Ipsen completes acquisition of Tercica
This article was originally published in Scrip
Ipsenhas completed its acquisition of Tercica for $9.00 per share, or around $373 million, after 90% of the 68.5 million total votable shares were cast in favour of the acquisition at a special meeting held on October 16th. The acquisition of Tercica is part of Ipsen's "three steps to globalisation", which it announced in June, involving the acquisitions of Vernalis's US subsidiary, Vernalis Pharmaceuticals, and Octagen's assets related to OBI-1, a recombinant porcine Factor VIII, as well as Tercica. The Vernalis and Octagen acquisitions both closed in July.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.